3 results match your criteria: "Indiana Center of Musculoskeletal Health[Affiliation]"
Raloxifene Stimulates Estrogen Signaling to Protect Against Age- and Sex-Related Intervertebral Disc Degeneration in Mice.
Front Bioeng Biotechnol
August 2022
Department of Mechanical and Energy Engineering, Indiana University-Purdue University Indianapolis, Indianapolis, IN, United States.
Estrogen agonist raloxifene is an FDA-approved treatment of osteoporosis in postmenopausal women, which may also be a promising prophylactic for painful intervertebral disc (IVD) degeneration. Here, we hypothesized that 1) aging and biological sex contribute to IVD degeneration by reducing estrogen signaling and that 2) raloxifene stimulates estrogen signaling to protect against age- and sex-related IVD degeneration in mice. 2.
View Article and Find Full Text PDFEditorial: Metabolic Adaptation of Muscle Tissue in Diseases Associated With Cachexia.
Front Cell Dev Biol
June 2022
IRCCS Istituto Ortopedico Galeazzi, Milan, Italy.
Suppression of Sost/Sclerostin and Dickkopf-1 Augment Intervertebral Disc Structure in Mice.
J Bone Miner Res
June 2022
Indiana Center of Musculoskeletal Health, Indianapolis, IN, USA.
Intervertebral disc (IVD) degeneration is a leading cause of low back pain, characterized by accelerated extracellular matrix breakdown and IVD height loss, but there is no approved pharmacological therapeutic. Deletion of Wnt ligand competitor Lrp5 induces IVD degeneration, suggesting that Wnt signaling is essential for IVD homeostasis. Therefore, the IVD may respond to neutralization of Wnt ligand competitors sost(gene)/sclerostin(protein) and/or dickkopf-1 (dkk1).
View Article and Find Full Text PDF